Johnson & Johnson MEDTECH — Amortization remained flat by 0.0% to $500.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $500.00M to $500.00M.
Higher amortization often reflects significant past acquisition activity or heavy investment in intellectual property.
This represents the periodic expense recognized for the allocation of the cost of intangible assets, such as patents and...
Commonly reported as part of segment-level depreciation and amortization in financial disclosures for M&A-active firms.
jnj_segment_medtech_amortization| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $300.00M | $300.00M | $300.00M | $300.00M | $300.00M | $400.00M | $400.00M | $400.00M | $400.00M | $400.00M | $500.00M | $500.00M | $500.00M | $500.00M | $500.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +33.3% | +0.0% | +0.0% | +0.0% | +0.0% | +25.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | +0.0% | +0.0% | +33.3% | +33.3% | +33.3% | +0.0% | +0.0% | +25.0% | +25.0% | +25.0% | +0.0% | +0.0% |